These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 18366923)

  • 1. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
    Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
    Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum C-reactive protein in the differential diagnosis of ovarian masses.
    Hefler-Frischmuth K; Hefler LA; Heinze G; Paseka V; Grimm C; Tempfer CB
    Eur J Obstet Gynecol Reprod Biol; 2009 Nov; 147(1):65-8. PubMed ID: 19619929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
    Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
    Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
    Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
    Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective evaluation of tumor markers in ovarian mature cystic teratoma and ovarian endometrioma.
    Kataoka T; Watanabe Y; Hoshiai H
    J Obstet Gynaecol Res; 2012 Aug; 38(8):1071-6. PubMed ID: 22568880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
    Ma S; Shen L; Qian N; Chen K
    Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical significance of serum CP2, CA125, salicylic acid and carcinoembryonic antigen in endometrial carcinoma].
    Wang ZQ; Wang JL; Yang JH; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):18-22. PubMed ID: 18366926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype.
    Kelly PJ; Archbold P; Price JH; Cardwell C; McCluggage WG
    J Clin Pathol; 2010 Feb; 63(2):169-73. PubMed ID: 20154039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of C12 multi-tumor marker protein chip in the diagnosis of gastrointestinal cancer: results of 329 surgical patients and suggestions for improvement.
    Yang XQ; Yan L; Chen C; Hou JX; Li Y
    Hepatogastroenterology; 2009; 56(94-95):1388-94. PubMed ID: 19950797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnosis of ovarian tumor by measuring tumor markers].
    Fukatsu T; Nakashima N; Takeuchi J
    Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
    Ayhan A; Guven S; Guven ES; Kucukali T
    Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
    Lai IR; Lee WJ; Huang MT; Lin HH
    Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Application of multi-tumor markers in ovarian carcinoma].
    Feng J; Qian H; Tian Y
    Zhonghua Fu Chan Ke Za Zhi; 1998 May; 33(5):284-6. PubMed ID: 10682440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis.
    Luo LY; Katsaros D; Scorilas A; Fracchioli S; Bellino R; van Gramberen M; de Bruijn H; Henrik A; Stenman UH; Massobrio M; van der Zee AG; Vergote I; Diamandis EP
    Cancer Res; 2003 Feb; 63(4):807-11. PubMed ID: 12591730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
    Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
    Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.